In the last year, the NIH has written and presented three works detailing their research on using JAK inhibitors (targeted immunosuppressants) to treat APS Type 1 manifestations. The results are promising for our community, and the NIH team is continuing their efforts to advance the research. We are grateful for their work and look forward to sharing further developments.
Below are links, in chronological order, to their research paper, video presentation, and short abstract explaining this work.
- Research Paper: This New England Journal of Medicine article details their findings of using the JAK inhibitor, Ruxolitinib, to treat 9 different manifestations in 5 patients.
- NIH Grand Rounds: This NIH Grand rounds lecture presents the team’s continued research success using Ruxolitinib, reporting that 20 of the 35 known APS 1 manifestations showed improvement through this therapy.
- Abstract: Finally, the NIH team’s latest research is presented in a short abstract explaining their continued search for the best JAK inhibitor to treat APS Type 1 manifestations in terms of maximum efficacy and minimal side effects.